Wepox Dispopen contains Recombinant Human Erythropoietin Alfa (20000 IU), a synthetic form of erythropoietin, a glycoprotein hormone that regulates erythropoiesis, the production of red blood cells. It is primarily indicated for the treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and those not yet on dialysis. Additionally, Wepox Dispopen is used to manage anemia in patients undergoing chemotherapy for non-myeloid malignancies, reducing the need for blood transfusions. The drug acts by stimulating erythroid progenitor cells in the bone marrow, thereby increasing red blood cell production and improving oxygen-carrying capacity. Administration is typically via subcutaneous or intravenous injection, with dosing individualized based on patient response and hemoglobin levels to avoid excessive erythropoiesis and associated risks such as hypertension and thromboembolic events. Monitoring of hemoglobin, hematocrit, and iron status is essential during therapy to optimize efficacy and safety. Wepox Dispopen should be used cautiously in patients with uncontrolled hypertension or hypersensitivity to erythropoietin products. Proper patient selection and adherence to recommended dosing guidelines are critical to minimize adverse effects and maximize therapeutic benefit in anemia management.